MEDIPURE PHARMACEUTICALS INC. ANNOUNCES APPOINTMENT OF DR. SAFWAT RABEA AS RESEARCH SCIENTIST - MEDICINAL CHEMISTRY

Vancouver, B.C. – April 27, 2018 – Medipure Pharmaceuticals Inc., a biopharmaceutical incubator committed to discovering and developing proprietary cannabinoid-derived prescription medications, today announced the appointment of industry veteran Dr. Safwat Rabea to its scientific team as Research Scientist – Medicinal Chemistry.

With a background in pharmaceuticals and medicinal and synthetic chemistry, Dr. Rabea will play a key role in developing Medipure’s novel drug pipeline through his expertise in structure-based drug design, high throughput screening, process development and scale-up for GMP production.

"We are very happy to have Dr. Rabea join our team at Medipure," said Boris Weiss, CEO of Medipure Pharmaceuticals. "With over 8 years of experience in drug discovery research in multiple research areas including inflammation, oncology and immunology covering target classes such as COX, CPCR and Kinases, we are looking forward to having him be a part of our revolutionary team of scientists."

Upon receiving his PhD in medicinal chemistry from the University of British Columbia in 2015, Dr. Rabea then joined a biotech company where he focused on the development of novel drugs for neurodegenerative diseases. Additionally, he holds a bachelor’s degree with a focus on Organic/Medicinal Chemistry. As the co-inventor of 1 U.S. patent and the author of 5 peer-reviewed scientific publications, he has also received a UBC International Doctoral Fellowship and a Mitacs Postdoctoral Fellowship award for his research.

ABOUT MEDIPURE
Medipure Pharmaceuticals is a biopharmaceutical incubator committed to discovering and developing proprietary endocannabinoid system-based prescription drugs for targeted diseases by regulating specific molecular mechanisms. Our core products target specific disease areas including pain management, mood disorders/anxiety, nausea, appetite, oncology, arthritis, dermatology and fatty liver disease (NASH).

Medipure Pharmaceuticals’ research and development is focused on having the greatest impact and benefit for patients worldwide. At the same time, we aim to make sure that our products are approved by regulators and well understood by physicians, healthcare providers and prospective patients.